WASHINGTON (August 26, 2020) – A team led by researchers at the George Washington University (GW) has established a controlled human hookworm infection (CHHI) model to accelerate the development of human hookworm vaccines.
WASHINGTON (Aug. 13, 2020) — Fingolimod, an FDA-approved immunosuppressive drug used to treat multiple sclerosis flare-ups, may be used to block HIV infection and reduce the latent reservoir. Researchers at the George Washington University (GW) published their novel findings in PLOS Pathogens.
Dr. Paul Brindley will be the new co-EiC of PLOS NTDs. Paul has been an editorial board member of PLOS NTDs for more than 10 years, a Deputy Editor since 2012, and guest co-EIC this past year.
The human protein apolipoprotein A-I binding protein (AIBP) inhibits HIV replication by targeting lipid rafts and reducing virus-cell fusion, according to a new study published in the premier American Society for Microbiology journal mBio by researchers from the George Washington University.
Paul Brindley, PhD, professor of microbiology, immunology, and tropical medicine, was awarded an Honorary Doctorate Degree of Science in Parisitology from Khon Kaen University in Thailand.
About two billion of the world’s poorest people are infected with parasitic worms. Treatments are available, but Jeffrey Bethony, a microbiologist at George Washington University in Washington DC, explains why only vaccines can eradicate infection.